Remove tag diagnosis
article thumbnail

Cost of disease-modifying therapies for multiple sclerosis continues to rise in US

Pharmaceutical Technology

While MS is not a terminal diagnosis, the effect of the disease on the CNS can significantly impact patients’ independence and disturb their daily lives. DMTs for MS have a high price tag, particularly in the US. However, they cannot provide a cure and have a very limited impact on halting disease progression.

Marketing 246
article thumbnail

Roche’s Early Alzheimer’s Blood Test Gets FDA Breakthrough Device Designation

XTalks

However, Roche has several CSF tests on the market, which include assays in the company’s Elecsys line that are used in conjunction with PET in the diagnosis and monitoring of the disease. We’re excited to help meet the growing need for additional diagnostic tools to enable a timely and accurate diagnosis for people with Alzheimer’s disease.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds December 15, 2023: Diversifying Clinical Trials: A Path Forward (Roxana Mehran, MD, FACC, FAHA, MSCAI, FESC)

Rethinking Clinical Trials

First, increasing diversity among trial participants must be a top priority in order to address health disparities and allow for optimal diagnosis and management of CVD in all. There are several strategies that will help increase diversity in CVD trials. With the current ability to become pregnant this can affect women up to the age of 50.

article thumbnail

Grand Rounds June 16, 2023: BeatPain Utah: Partnering With Community Health Centers Within a Socio-Technical Framework (Julie Fritz, PT, PhD, FAPTA; Guilherme Del Fiol, MD, PhD)

Rethinking Clinical Trials

However, persons in low-income and rural communities have significantly higher odds of receiving a prescription opioid for a new back pain diagnosis. Use of nonpharmacologic pain treatments is lower in rural settings and for persons of Hispanic/Latino ethnicity.

article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). “The Go-to-market strategies. The choice of where to launch an orphan drug is an important and difficult decision.

Drugs 147
article thumbnail

The FDA and Aduhelm: WTF?

World of DTC Marketing

Alzheimer’s really is a devastating diagnosis, and if Biogen had actually produced a game-changing product to slow its worst symptoms, it would have an immeasurable impact on millions of lives. Not to mention the $56,000 annual price tag. What’s more, 40 percent of those subjects suffered side effects, including severe brain swelling.

Drugs 218
article thumbnail

Blue Note leukaemia DTx gets FDA breakthrough tag

pharmaphorum

“The advancement of innovative therapeutic options for the treatment of the associated distress that often follows a diagnosis is promising for patients and addresses an unmet need,” said Areej El-Jawahri of Massachusetts General Hospital. The post Blue Note leukaemia DTx gets FDA breakthrough tag appeared first on.